HeartBeam to Present at LD Micro Main Event XV Conference
October 13 2022 - 8:31AM
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology
company that has developed the first and only 3D-vector ECG
platform for heart attack detection anytime, anywhere, will present
at the LD Micro Main Event XV Conference being held at the Luxe
Sunset Boulevard Hotel in Los Angeles, CA on October 25-27,
2022.
HeartBeam Chief Executive Officer and Founder Branislav Vajdic,
PhD will conduct in-person one-on-one meetings and deliver the
Company’s presentation which can be viewed live and via replay at
the webcast link below and will also be available on the HeartBeam
investor relations website at ir.heartbeam.com.
LD Micro Main Event XV Conference Date: October 25-27,
2022 Location: Los Angeles, CA Presentation Time: Tuesday, October
25, 2022, at 4:30 pm PT (7:30 pm ET) in TRACK 3 Webcast
Registration: https://me22.sequireevents.com/ Format: In-person
1x1’s and Presentations Speakers: Chief Executive Officer and
Founder Branislav Vajdic, PhD Conference Website: Click here
For more information on the LD Micro Main Event XV Conference,
or to schedule a one-on-one meeting with HeartBeam management,
please contact your conference representative or you may also email
your request to BEAT@mzgroup.us or call Chris Tyson at (949)
491-8235.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform for
heart attack detection anytime, anywhere. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to determine if symptoms are due to a heart attack,
quickly and easily, so care can be expedited, if required.
HeartBeam has two patented products in development. HeartBeam AIMI™
is software for acute care settings that provides a 3D comparison
of baseline and symptomatic 12-lead ECG to more accurately identify
a heart attack. HeartBeam AIMIGo™ is the first and only credit
card-sized 12-lead output ECG device coupled with a smart phone app
and cloud-based diagnostic software system to facilitate remote
heart attack detection. HeartBeam AIMI and AIMIGo have not yet been
cleared by the US Food and Drug Administration (FDA) for marketing
in the USA or other geographies. For more information, visit
HeartBeam.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221013005318/en/
Investor Relations Contact: Chris Tyson Executive
Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
Media Contact: Capwell Communications
media@capwellcomm.com 949-999-3303
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Apr 2023 to Apr 2024